文献速递神经肿瘤

早期ADC升高预测H3K27M突变型弥漫性中线胶质瘤对Dordaviprone治疗的良好反应

Early increase in apparent diffusion coefficient predicts favorable response to Dordaviprone (ONC201) therapy in H3K27M-mutant diffuse midline glioma.
PubMed 文献 · Neuro Oncol · 2026-07-21

本研究对83例接受Dordaviprone治疗的H3K27M突变型弥漫性中线胶质瘤患者进行影像分析,最终纳入38例标准化治疗患者。结果显示,在放疗后进展前接受治疗的患者中,第3周期ADC升高的肿瘤中位OS为732天,ADC降低者为360天(p=0.0149),相应PFS分别为334天和110天(p=0.0132)。早期ADC升高与CSF代谢改变相关,提示ADC可作为潜在生物标志物。

要点

  • 早期肿瘤体积或RAPNO标准变化不能预测OS或PFS。
  • 第3周期ADC升高与更长的OS和PFS相关。
  • ADC升高与CSF还原应激代谢物改变相关。

核心结论

  • 早期ADC升高与Dordaviprone治疗H3K27M-DMG的更好反应相关,并伴随CSF代谢改变,提示ADC值得前瞻性验证作为生物标志物。

研究设计与样本

  • 对已完成研究中接受Dordaviprone治疗的患者(n=83)进行集中神经影像学审阅、ADC直方图分析和功能扩散映射(fDM),最终分析纳入38例接受标准化Dordaviprone剂量和治疗方案的患者。

主要发现

  • 在进展前队列中,早期体积或横断面RAPNO标准变化不能预测总生存(OS)或无进展生存(PFS)。
  • 放疗后进展前接受Dordaviprone治疗的患者中,第3周期ADC升高(细胞密度降低)者中位OS为732天,ADC降低(细胞密度增加)者为360天(p=0.0149)。
  • 相应中位PFS分别为334天和110天(p=0.0132)。
  • fDM分析的ADC时空变化在亚组分析中与结局无关,但在个体患者时间序列中显示预测模式。
  • 按ADC变化分层的CSF代谢组学显示,Dordaviprone应答者中还原应激代谢物存在差异,将ADC升高与Dordaviprone驱动的代谢效应联系起来。

临床怎么用

  • 在放疗后进展前接受Dordaviprone治疗的患者中,可考虑监测第3周期ADC变化以辅助评估治疗反应。

局限性

  • fDM分析在亚组中未显示与结局相关,仅个体时间序列显示预测模式。
  • CSF代谢组学分析为 anecdotal 性质,需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Dordaviprone (ONC201) is the first FDA-approved therapy for H3K27M-mutant diffuse midline glioma (DMG). However, therapeutic response varies among patients, and no imaging biomarkers currently predict long-term benefit. Diffusion-weighted MRI and apparent diffusion coefficient (ADC) obtained during standard clinical imaging reflects tissue cellularity and necrosis, offering potential as an early response indicator. METHODS: Clinical and imaging data from patients treated with dordaviprone (n = 83) on completed studies underwent centralized neuroradiology review, ADC histogram analysis, and Functional Diffusion Mapping (fDM), which were compared and correlated to CSF tumor DNA (tDNA) and metabolomics when available. Final analysis included 38 patients receiving standardized dordaviprone dosing and treatment schedule. RESULTS: In the pre-progression cohort, early changes in volumetric or cross-sectional RAPNO criteria were not predictive of overall (OS) or progression-free survival (PFS). Importantly, in patients treated pre-progression with dordaviprone post-radiation, tumors with increased diffusion ADC (reduced cellularity) at cycle 3 demonstrated median OS of 732 days versus 360 days for those with decreased ADC (increased cellularity, p = 0.0149); with corresponding PFS of 334 versus 110 days (p = 0.0132).fDM analysis of spatio-temporal changes of ADC did not correlate with outcomes in a sub-cohort analysis but demonstrated predictive patterns in individual patient time course series. CSF metabolomics stratified by ADC change revealed differences in reductive stress metabolites among dordaviprone responders, linking ADC elevation to dordaviprone -driven metabolic effects. CONCLUSION: Early increase in ADC correlates with improved response to dordaviprone in H3K27M-DMG and correlates with CSF metabolic changes, suggesting ADC warrants prospective validation as a biomarker. Dordaviprone (ONC201)is the first FDA-approved treatment for recurrent H3K27M-mutant diffuse midline glioma, but patient responses vary and no imaging biomarkers currently predict benefit. Diffusion MRI [apparent diffusion coefficient (ADC)], which reflects tumor cellularity, is obtained during routine care. In patients treated with dordaviprone after radiation and before progression, early changes in tumor size did not predict survival. However, tumors showing increased ADC after two cycles were associated with longer overall survival and delayed progression. Anecdotal analyses of spinal fluid metabolites showed patterns consistent with dordaviprone’s expected biological effects, supporting further study of early ADC increase as a potential biomarker.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. Lau BC, Ajaero DP, Hoff BA, et al. Early increase in apparent diffusion coefficient predicts favorable response to Dordaviprone (ONC201) therapy in H3K27M-mutant diffuse midline glioma. Neuro Oncol. 2026. PMID: 42482168. doi:10.1093/neuonc/noag164

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。